Literature DB >> 28349676

Flourodeoxyglucose positron emission tomography scan may be helpful in the case of ductal variant prostate cancer when prostate specific membrane antigen ligand positron emission tomography scan is negative.

Louise M McEwan1, David Wong1, John Yaxley2.   

Abstract

Gallium-68 prostate specific membrane antigen ligand (Ga-68 PSMA) positron emission tomography/computed tomography (PET/CT) scanning is emerging as a useful imaging modality for the staging of suspected and known recurrent or metastatic prostate cancer and in staging of newly diagnosed higher grade prostate cancer. However, we have observed at our institution that in some cases of the more aggressive ductal variant, Ga-68 PSMA uptake has sometimes been poor compared with prominent 18-flourodeoxyglucose (F-18 FDG) avidity seen in F-18 FDG PET/CT, which would suggest that FDG PET/CT scans are important in staging of ductal pattern prostate cancer.
© 2017 The Royal Australian and New Zealand College of Radiologists.

Entities:  

Keywords:  zzm321990FDG PETzzm321990; zzm321990PSMA PETzzm321990; ductal variant; prostate carcinoma; staging

Mesh:

Substances:

Year:  2017        PMID: 28349676     DOI: 10.1111/1754-9485.12605

Source DB:  PubMed          Journal:  J Med Imaging Radiat Oncol        ISSN: 1754-9477            Impact factor:   1.735


  5 in total

1.  Incidentalomas of the prostate detected by 18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography.

Authors:  Miles P Mannas; Taeweon Lee; Maral Pourghiasian; Don C Wilson; Peter C Black
Journal:  Can Urol Assoc J       Date:  2019-11-29       Impact factor: 1.862

Review 2.  Optimizing the diagnosis and management of ductal prostate cancer.

Authors:  Weranja Ranasinghe; Daniel D Shapiro; Miao Zhang; Tharakeswara Bathala; Nora Navone; Timothy C Thompson; Bradley Broom; Ana Aparicio; Shi-Ming Tu; Chad Tang; John W Davis; Louis Pisters; Brian F Chapin
Journal:  Nat Rev Urol       Date:  2021-04-06       Impact factor: 14.432

3.  Intense fluoro-2-deoxyglucose uptake in high-grade prostatic adenocarcinoma with negligible prostate-specific membrane antigen expression.

Authors:  Tansel Cakir; Selcuk Guven; Bahar Muezzinoglu; Cengiz Erol; Mustafa Yucel Boz; Tamer Atasever
Journal:  Urol Ann       Date:  2019 Oct-Dec

Review 4.  Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer.

Authors:  Mahasha P J Perera; Patrick B Thomas; Gail P Risbridger; Renea Taylor; Arun Azad; Michael S Hofman; Elizabeth D Williams; Ian Vela
Journal:  Cancers (Basel)       Date:  2022-01-20       Impact factor: 6.639

Review 5.  Beyond the Prognostic Value of 2-[18F]FDG PET/CT in Prostate Cancer: A Case Series and Literature Review Focusing on the Diagnostic Value and Impact on Patient Management.

Authors:  Roberto Borea; Diletta Favero; Alberto Miceli; Maria Isabella Donegani; Stefano Raffa; Annalice Gandini; Malvina Cremante; Cecilia Marini; Gianmario Sambuceti; Elisa Zanardi; Silvia Morbelli; Giuseppe Fornarini; Sara Elena Rebuzzi; Matteo Bauckneht
Journal:  Diagnostics (Basel)       Date:  2022-02-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.